PE20201502A1 - Compuestos de aminoacidos y metodos de uso - Google Patents
Compuestos de aminoacidos y metodos de usoInfo
- Publication number
- PE20201502A1 PE20201502A1 PE2020001357A PE2020001357A PE20201502A1 PE 20201502 A1 PE20201502 A1 PE 20201502A1 PE 2020001357 A PE2020001357 A PE 2020001357A PE 2020001357 A PE2020001357 A PE 2020001357A PE 20201502 A1 PE20201502 A1 PE 20201502A1
- Authority
- PE
- Peru
- Prior art keywords
- deuterium
- compounds
- methods
- amino acid
- acid compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639988P | 2018-03-07 | 2018-03-07 | |
| US201862690933P | 2018-06-27 | 2018-06-27 | |
| PCT/US2019/021243 WO2019173653A1 (en) | 2018-03-07 | 2019-03-07 | Amino acid compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20201502A1 true PE20201502A1 (es) | 2020-12-29 |
Family
ID=67844341
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001357A PE20201502A1 (es) | 2018-03-07 | 2019-03-07 | Compuestos de aminoacidos y metodos de uso |
| PE2025000569A PE20251320A1 (es) | 2018-03-07 | 2019-03-07 | Compuestos de aminoacidos y metodos de uso |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2025000569A PE20251320A1 (es) | 2018-03-07 | 2019-03-07 | Compuestos de aminoacidos y metodos de uso |
Country Status (35)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3509590A4 (en) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| MX394210B (es) | 2017-02-28 | 2025-03-04 | Morphic Therapeutic Inc | INHIBIDORES DE INTEGRINA AVß6. |
| FI3761980T3 (fi) * | 2018-03-07 | 2024-02-21 | Pliant Therapeutics Inc | Aminohappoyhdisteitä ja käyttömenetelmiä |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| KR102767739B1 (ko) | 2018-06-27 | 2025-02-12 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| SI3844162T1 (sl) | 2018-08-29 | 2025-06-30 | Morphic Therapeutic, Inc. | Zaviralci integrina alfa v beta6 |
| WO2020047239A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| ES3013256T3 (en) | 2018-10-30 | 2025-04-11 | Gilead Sciences Inc | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| FI3873884T3 (fi) | 2018-10-30 | 2025-02-24 | Gilead Sciences Inc | 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa |
| JP7189368B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４ベータ７インテグリンの阻害のための化合物 |
| EP3873605B1 (en) | 2018-10-30 | 2024-10-23 | Gilead Sciences, Inc. | Compounds for inhibition of alpha4beta7 integrin |
| CN114173803A (zh) * | 2019-04-08 | 2022-03-11 | 普利安特治疗公司 | 氨基酸化合物的剂型和方案 |
| WO2021030438A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| US20230060422A1 (en) * | 2019-12-20 | 2023-03-02 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
| CN115989235A (zh) * | 2020-05-07 | 2023-04-18 | 普利安特治疗公司 | 使用氨基酸化合物治疗呼吸系统疾病的方法 |
| EP4247472A4 (en) | 2020-11-19 | 2024-10-09 | Pliant Therapeutics, Inc. | INTEGRIN INHIBITORS AND USES THEREOF |
| MX2023012794A (es) * | 2021-04-30 | 2023-12-15 | Pliant Therapeutics Inc | Regímenes de dosificación expandidos para inhibidores de integrina. |
| JP2025518533A (ja) * | 2022-05-18 | 2025-06-17 | プライアント・セラピューティクス・インコーポレイテッド | インテグリン阻害剤の安定化 |
| EP4626878A1 (en) | 2022-12-02 | 2025-10-08 | Neumora Therapeutics, Inc. | Methods of treating neurological disorders |
| WO2024125634A1 (zh) * | 2022-12-16 | 2024-06-20 | 西藏海思科制药有限公司 | 一种四氢萘啶类化合物及其在医药上的应用 |
| WO2024155965A2 (en) * | 2023-01-21 | 2024-07-25 | Pliant Therapeutics, Inc. | Biomarkers for use in integrin inhibitor therapy |
| WO2024235299A1 (zh) * | 2023-05-17 | 2024-11-21 | 西藏海思科制药有限公司 | 一种羧基衍生物及其在医药上的应用 |
| WO2025024590A1 (en) * | 2023-07-24 | 2025-01-30 | The Johns Hopkins University | Compositions and methods to treat mucus-related diseases |
| WO2025067384A1 (zh) * | 2023-09-28 | 2025-04-03 | 成都微芯药业有限公司 | 一类氨基酸整联蛋白抑制剂、其制备方法及其应用 |
| US20250197393A1 (en) * | 2023-12-14 | 2025-06-19 | Pliant Therapeutics, Inc. | Integrin inhibitor and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6361764B2 (en) | 1996-12-13 | 2002-03-26 | Societe L'oreal S.A. | Insoluble s-triazine derivatives and their use as UV filters |
| KR20010033248A (ko) * | 1997-12-17 | 2001-04-25 | 폴락 돈나 엘. | 인테그린 수용체 길항제 |
| US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| US7119098B2 (en) * | 2000-06-15 | 2006-10-10 | Pharmacia Corporation | Heteroarylakanoic acids as intergrin receptor antagonists |
| JP4272338B2 (ja) | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
| MXPA03011046A (es) | 2001-06-01 | 2004-06-25 | Elan Pharm Inc | Hidroxialquilaminas. |
| DE10233500A1 (de) | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
| EP1537072A1 (en) | 2002-09-10 | 2005-06-08 | Pharmacia & Upjohn Company LLC | Substituted aminoethers for the treatment of alzheimer s disease |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| EP1870400A1 (en) | 2006-06-08 | 2007-12-26 | Boehringer Ingelheim Pharma GmbH & Co. KG | Salts and crystalline salt forms of an 2-indolinone derivative |
| UA104590C2 (ru) | 2008-06-06 | 2014-02-25 | Берингер Ингельхайм Интернациональ Гмбх | Капсулированная лекарственная форма, содержащая суспензионную композицию производной индолинона |
| UA107560C2 (uk) | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
| WO2014015054A1 (en) * | 2012-07-18 | 2014-01-23 | Saint Louis University | Beta amino acid derivatives as integrin antagonists |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| WO2015048819A1 (en) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| WO2016145258A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| GB201604681D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| EP3442352A4 (en) | 2016-04-14 | 2020-03-11 | Mars, Incorporated | COMPOUNDS FOR MODULATING THE ACTIVITY OF CALCIUM-SENSITIVE RECEPTORS FOR MODULATING THE TASTE OF KOKUMI AND ANIMAL FEED PRODUCTS THEREFORE |
| US11192889B2 (en) * | 2016-07-05 | 2021-12-07 | The Rockefeller University | Tetrahydronaphthyridinepentanamide integrin antagonists |
| EP3509590A4 (en) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE |
| JP2019536812A (ja) | 2016-12-12 | 2019-12-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| MX394210B (es) | 2017-02-28 | 2025-03-04 | Morphic Therapeutic Inc | INHIBIDORES DE INTEGRINA AVß6. |
| FI3761980T3 (fi) * | 2018-03-07 | 2024-02-21 | Pliant Therapeutics Inc | Aminohappoyhdisteitä ja käyttömenetelmiä |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| WO2020047239A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| WO2020047207A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutics, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| CN114173803A (zh) | 2019-04-08 | 2022-03-11 | 普利安特治疗公司 | 氨基酸化合物的剂型和方案 |
| CN115989235A (zh) | 2020-05-07 | 2023-04-18 | 普利安特治疗公司 | 使用氨基酸化合物治疗呼吸系统疾病的方法 |
-
2019
- 2019-03-07 FI FIEP19765136.7T patent/FI3761980T3/fi active
- 2019-03-07 WO PCT/US2019/021243 patent/WO2019173653A1/en not_active Ceased
- 2019-03-07 HU HUE19765136A patent/HUE065887T2/hu unknown
- 2019-03-07 IL IL277146A patent/IL277146B2/en unknown
- 2019-03-07 CU CU2020000066A patent/CU24684B1/es unknown
- 2019-03-07 JP JP2020521559A patent/JP6866535B2/ja active Active
- 2019-03-07 PT PT197651367T patent/PT3761980T/pt unknown
- 2019-03-07 MX MX2020009253A patent/MX2020009253A/es unknown
- 2019-03-07 SM SM20240155T patent/SMT202400155T1/it unknown
- 2019-03-07 LT LTEPPCT/US2019/021243T patent/LT3761980T/lt unknown
- 2019-03-07 EP EP23205993.1A patent/EP4328230A3/en not_active Withdrawn
- 2019-03-07 SI SI201930710T patent/SI3761980T1/sl unknown
- 2019-03-07 PE PE2020001357A patent/PE20201502A1/es unknown
- 2019-03-07 US US16/296,194 patent/US10793564B2/en active Active
- 2019-03-07 CA CA3093225A patent/CA3093225A1/en active Pending
- 2019-03-07 KR KR1020207026985A patent/KR102787602B1/ko active Active
- 2019-03-07 JO JOP/2020/0212A patent/JOP20200212A1/ar unknown
- 2019-03-07 IL IL305296A patent/IL305296A/en unknown
- 2019-03-07 CR CR20200452A patent/CR20200452A/es unknown
- 2019-03-07 ES ES19765136T patent/ES2972512T3/es active Active
- 2019-03-07 AU AU2019230209A patent/AU2019230209B2/en active Active
- 2019-03-07 PE PE2025000569A patent/PE20251320A1/es unknown
- 2019-03-07 CN CN201980030750.4A patent/CN112135612B/zh active Active
- 2019-03-07 KR KR1020257009595A patent/KR20250048478A/ko active Pending
- 2019-03-07 MD MDE20210065T patent/MD3761980T2/ro unknown
- 2019-03-07 TW TW108107688A patent/TWI892960B/zh active
- 2019-03-07 RS RS20240183A patent/RS65170B1/sr unknown
- 2019-03-07 EP EP24207882.2A patent/EP4509512A3/en not_active Withdrawn
- 2019-03-07 DK DK19765136.7T patent/DK3761980T3/da active
- 2019-03-07 BR BR112020018064-5A patent/BR112020018064A2/pt active Search and Examination
- 2019-03-07 SG SG11202008609UA patent/SG11202008609UA/en unknown
- 2019-03-07 HR HRP20240234TT patent/HRP20240234T1/hr unknown
- 2019-03-07 PL PL19765136.7T patent/PL3761980T3/pl unknown
- 2019-03-07 EP EP19765136.7A patent/EP3761980B1/en active Active
-
2020
- 2020-06-26 US US16/914,209 patent/US11560376B2/en active Active
- 2020-08-31 ZA ZA2020/05437A patent/ZA202005437B/en unknown
- 2020-09-04 CL CL2020002290A patent/CL2020002290A1/es unknown
- 2020-09-04 MX MX2022014456A patent/MX2022014456A/es unknown
- 2020-09-06 SA SA520420102A patent/SA520420102B1/ar unknown
- 2020-09-07 CO CONC2020/0011085A patent/CO2020011085A2/es unknown
- 2020-09-07 PH PH12020551395A patent/PH12020551395A1/en unknown
- 2020-10-06 EC ECSENADI202063227A patent/ECSP20063227A/es unknown
-
2021
- 2021-04-07 JP JP2021065309A patent/JP7273882B2/ja active Active
-
2022
- 2022-12-19 US US18/084,307 patent/US20230271960A1/en not_active Abandoned
-
2023
- 2023-04-28 JP JP2023074346A patent/JP7624025B2/ja active Active
-
2024
- 2024-09-13 US US18/885,075 patent/US20250223288A1/en active Pending
-
2025
- 2025-01-17 JP JP2025006716A patent/JP2025081308A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20201502A1 (es) | Compuestos de aminoacidos y metodos de uso | |
| ECSP21032717A (es) | Compuestos de aminoácidos y métodos de uso | |
| PE20211411A1 (es) | Compuestos de anillo fusionado | |
| PE20170127A1 (es) | Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas | |
| PE20141404A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
| PE20142098A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| AR068075A1 (es) | Compuestos de piperazina con accion herbicida. proceso de preparacion | |
| PE20110835A1 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| UY37160A (es) | COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6 | |
| NI201800033A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3piridil]-1-isopropil-imidazo[4, 5-c]quinolin -2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer. | |
| PE20181269A1 (es) | Agonistas del receptor de apelina y metodos de uso | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| AR078201A1 (es) | Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos | |
| AR081039A1 (es) | Inhibidores biciclicos fusionados de quinasa | |
| CO5631438A2 (es) | Profarmacos de aminoacidos excitadores | |
| PE20161444A1 (es) | 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina | |
| EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| MX2020011339A (es) | Polímero catiónico y uso para suministro de biomolecúla. | |
| PE20191486A1 (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CANCER | |
| PE20141190A1 (es) | Isoxazolinas como agentes terapeuticos | |
| CO2023016295A2 (es) | Regímenes de dosificación expandidos para inhibidores de integrina | |
| PE20091455A1 (es) | Triazolopiridazinas como inhibidores de par1, su preparacion y uso como medicamentos | |
| MX390507B (es) | Compuestos de amida y su uso. |